

# **Middle East & Africa Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Type (Amyloid-related Markers, Tau-related Markers), By Technology, By End-use, By Country, And Segment Forecasts, 2025 - 2033**

<https://marketpublishers.com/r/MDFA94DF7466EN.html>

Date: August 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: MDFA94DF7466EN

## **Abstracts**

### Market Size & Trends

The Middle East & Africa blood-based biomarker for Alzheimer's disease diagnostics market size was estimated at USD 6.22 million in 2024 and is expected to reach USD 13.11 million by 2033, growing at a CAGR of 9.77% from 2025 to 2033. Rising awareness of neurodegenerative diseases, coupled with an aging population across the region, is fueling demand for early detection tools. Traditionally, Alzheimer's diagnosis has relied on expensive and invasive methods such as PET imaging or cerebrospinal fluid (CSF) testing, which are often limited in availability across MEA. Blood-based biomarkers offer a cost-effective, scalable, and minimally invasive alternative, making them particularly attractive in regions with constrained healthcare infrastructure.

As governments prioritize healthcare modernization and invest in early detection programs, adoption of blood biomarker tests is expected to expand. Market growth is also supported by international collaborations, local clinical trials, and the entry of global biotech companies into MEA, further bridging the gap between advanced Western technologies and regional healthcare needs.

Population aging and the regional dementia burden are powerful demand drivers. The Arab world had ~1.33 million people with dementia in 2021, while the WHO estimates 57 million globally (60-70% Alzheimer's), with most cases in low/middle-income countries-categories that include many MEA markets. In Africa, studies report dementia

incidence ~13.3 per 1,000 person-years and wide prevalence ranges (2.3–20%), underscoring unmet diagnostic need. Five reasons this pushes BBMs: (1) growing at-risk 65+ cohorts; (2) earlier detection improves care planning; (3) primary-care-friendly testing expands reach; (4) caregiver and societal burden pressures ministries to act; and (5) health-system KPI shifts toward chronic-disease management. Country snapshots illustrate heterogeneity: Lebanon shows high point prevalence (~828/100k), while the UAE is lower (~652/100k)-but rapid population aging and high health spending can still sustain demand. Together, these epidemiological realities create a durable, multi-year addressable market for AD BBMs.

Capital flows into MEA healthcare expand diagnostic capacity and BBM adoption. Saudi Arabia's Vision 2030 Health Sector Transformation Program is overhauling delivery models, while 2024 budget updates cite USD 57 billion for health/social development-funds that often translate into new labs, LIMS, and quality programs.

## MEA Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East & Africa blood-based biomarker for Alzheimer's disease diagnostics market report based on type, technology, end-use, and country:

Type Outlook (Revenue, USD Million, 2021 - 2033)

Amyloid-related markers

Tau-related markers

Neurodegeneration

Others

Technology Outlook (Revenue, USD Million, 2021 - 2033)

Immunoassays

Mass spectrometry-based assays

Next-generation platforms

Others

End-use Outlook (Revenue, USD Million, 2021 - 2033)

Clinical laboratories & hospital labs

Pharma & biotech

Academic & research institutes

Others

Country Outlook (Revenue, USD Million, 2021 - 2033)

South Africa

Saudi Arabia

UAE

Kuwait

**This report can be delivered to the clients within 3 Business Days**

## Contents

### **CHAPTER 1. MEA BLOOD-BASED BIOMARKER FOR ALZHEIMER'S DISEASE DIAGNOSTICS MARKET: METHODOLOGY AND SCOPE**

- 1.1. Market Segmentation and Scope
  - 1.1.1. Segment Definitions
    - 1.1.1.1. Type Segment
    - 1.1.1.2. Technology Segment
    - 1.1.1.3. End Use Segment
- 1.2. Estimates and Forecast Timeline
- 1.3. Objectives
  - 1.3.1. Objective - 1
  - 1.3.2. Objective - 2
  - 1.3.3. Objective - 3
- 1.4. Research Methodology
- 1.5. Information Procurement
  - 1.5.1. Purchased Database
  - 1.5.2. GVR's Internal Database
  - 1.5.3. Secondary Sources
  - 1.5.4. Primary Research
- 1.6. Information or Data Analysis
  - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Validation
- 1.8. Model Details
  - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. List of Abbreviations

### **CHAPTER 2. MEA BLOOD-BASED BIOMARKER FOR ALZHEIMER'S DISEASE DIAGNOSTICS MARKET: EXECUTIVE SUMMARY**

- 2.1. Market Snapshot
- 2.2. Type and Technology Snapshot
- 2.3. End Use Snapshot
- 2.4. Competitive Landscape Snapshot

### **CHAPTER 3. MEA BLOOD-BASED BIOMARKER FOR ALZHEIMER'S DISEASE DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE**

- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
  - 3.2.1. Parent Market Outlook
  - 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
  - 3.4.1. Regulatory approvals and clinical validation
  - 3.4.2. Rising demand for early and non-invasive diagnosis
  - 3.4.3. Integration with disease-modifying therapies (DMTS)
- 3.5. Market Restraint Analysis
  - 3.5.1. Reimbursement and coverage challenges
  - 3.5.2. Standardization and validation barriers
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
- 3.8. Pipeline Analysis

## **CHAPTER 4. MEA BLOOD-BASED BIOMARKER FOR ALZHEIMER'S DISEASE DIAGNOSTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS**

- 4.1. MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Type Movement Analysis
- 4.2. Amyloid-related markers
  - 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3. Tau-related markers
  - 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Neurodegeneration
  - 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Others
  - 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 5. MEA BLOOD-BASED BIOMARKER FOR ALZHEIMER'S DISEASE DIAGNOSTICS MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS**

- 5.1. MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Technology Movement Analysis
- 5.2. Immunoassays
  - 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3. Mass spectrometry-based assays

- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Next-generation platforms
  - 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Others
  - 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 6. MEA BLOOD-BASED BIOMARKER FOR ALZHEIMER'S DISEASE DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS**

- 6.1. MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: End Use Movement Analysis
- 6.2. Clinical laboratories & hospital labs
  - 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3. Pharma & biotech
  - 6.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Academic & research institutes
  - 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Others
  - 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 7. MEA BLOOD-BASED BIOMARKER FOR ALZHEIMER'S DISEASE DIAGNOSTICS MARKET: REGIONAL BUSINESS ANALYSIS**

- 7.1. Regional Market Snapshot
- 7.2. Middle East and Africa
  - 7.2.1. Middle East and Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  - 7.2.2. South Africa
    - 7.2.2.1. South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    - 7.2.2.2. Key Country Dynamics
    - 7.2.2.3. Regulatory Framework
    - 7.2.2.4. Reimbursement Scenario
    - 7.2.2.5. Competitive Scenario
  - 7.2.3. Saudi Arabia
    - 7.2.3.1. Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    - 7.2.3.2. Key Country Dynamics
    - 7.2.3.3. Regulatory Framework

7.2.3.4. Reimbursement Scenario

7.2.3.5. Competitive Scenario

7.2.4. UAE

7.2.4.1. UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)

7.2.4.2. Key Country Dynamics

7.2.4.3. Regulatory Framework

7.2.4.4. Reimbursement Scenario

7.2.4.5. Competitive Scenario

7.2.5. Kuwait

7.2.5.1. Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)

7.2.5.2. Key Country Dynamics

7.2.5.3. Regulatory Framework

7.2.5.4. Reimbursement Scenario

7.2.5.5. Competitive Scenario

## **CHAPTER 8. COMPETITIVE LANDSCAPE**

8.1. Company Categorization

8.2. Strategy Mapping

8.2.1. NEW PRODUCT LAUNCH

8.2.2. PARTNERSHIPS

8.2.3. ACQUISITION

8.2.4. COLLABORATION

8.2.5. FUNDING

8.3. Key Company Market Share Analysis, 2024

8.4. Company Heat Map Analysis

8.5. Company Profiles

8.5.1. F. Hoffmann-La Roche Ltd

8.5.1.1. Company Overview

8.5.1.2. Financial Performance

8.5.1.3. Product Benchmarking

8.5.1.4. Strategic Initiatives

8.5.2. Quanterix

8.5.2.1. Company Overview

8.5.2.2. Financial Performance

8.5.2.3. Product Benchmarking

8.5.2.4. Strategic Initiatives

### 8.5.3. Fujirebio

- 8.5.3.1. Company Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives

### 8.5.4. C2N Diagnostics

- 8.5.4.1. Company Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives

### 8.5.5. Quest Diagnostics Incorporated

- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives

### 8.5.6. ALZpath

- 8.5.6.1. Company Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives

### 8.5.7. Bio-Techne

- 8.5.7.1. Company Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives

### 8.5.8. Alamar Biosciences, Inc.

- 8.5.8.1. Company Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives

### 8.5.9. Beckman Coulter

- 8.5.9.1. Company Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives

## List Of Tables

### LIST OF TABLES

Table 1 List Of Abbreviation

Table 2 Middle East and Africa Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)

Table 3 Middle East and Africa Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)

Table 4 Middle East and Africa Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 5 South Africa Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)

Table 6 South Africa Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)

Table 7 South Africa Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 8 Saudi Africa Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)

Table 9 Saudi Africa Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)

Table 10 Saudi Africa Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 11 UAE Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)

Table 12 UAE Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)

Table 13 UAE Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

Table 14 Kuwait Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)

Table 15 Kuwait Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)

Table 16 Kuwait Blood-Based Biomarker For Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

## List Of Figures

### LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Market summary
- Fig. 4 Market segmentation & scope
- Fig. 5 Market size and growth prospects
- Fig. 6 MEA blood-based biomarker for Alzheimer's disease diagnostics market - Key market driver analysis
- Fig. 7 MEA blood-based biomarker for Alzheimer's disease diagnostics market - Key market restraint analysis
- Fig. 8 Penetration & growth prospect mapping
- Fig. 9 MEA blood-based biomarker for Alzheimer's disease diagnostics market - Porter's analysis
- Fig. 10 MEA blood-based biomarker for Alzheimer's disease diagnostics market - PESTEL analysis
- Fig. 11 MEA blood-based biomarker for Alzheimer's disease diagnostics market Type outlook key takeaways
- Fig. 12 MEA blood-based biomarker for Alzheimer's disease diagnostics market : Type movement analysis
- Fig. 13 Amyloid-related markers market estimates, 2021 - 2033 (USD Million)
- Fig. 14 Tau-related markers market estimates, 2021 - 2033 (USD Million)
- Fig. 15 Neurodegeneration market estimates, 2021 - 2033 (USD Million)
- Fig. 16 Others market estimates, 2021 - 2033 (USD Million)
- Fig. 17 MEA blood-based biomarker for Alzheimer's disease diagnostics market technology outlook key takeaways
- Fig. 18 MEA blood-based biomarker for Alzheimer's disease diagnostics market : technology movement analysis
- Fig. 19 Immunoassays market estimates, 2021 - 2033 (USD Million)
- Fig. 20 Mass spectrometry-based assays market estimates, 2021 - 2033 (USD Million)
- Fig. 21 Next-generation platforms market estimates, 2021 - 2033 (USD Million)
- Fig. 22 Others market estimates, 2021 - 2033 (USD Million)
- Fig. 23 MEA blood-based biomarker for Alzheimer's disease diagnostics market end use outlook key takeaways
- Fig. 24 MEA blood-based biomarker for Alzheimer's disease diagnostics market : end use movement analysis

Fig. 25 Clinical laboratories & hospital labs market estimates, 2021 - 2033 (USD Million)

Fig. 26 Pharma & biotech market estimates, 2021 - 2033 (USD Million)

Fig. 27 Academic & research institutes market estimates, 2021 - 2033 (USD Million)

Fig. 28 Others market estimates, 2021 - 2033 (USD Million)

Fig. 29 MEA marketplace: Key takeaways

Fig. 30 South Africa market estimates, 2021 - 2033 (USD Million)

Fig. 31 Saudi Arabia market estimates, 2021 - 2033 (USD Million)

Fig. 32 UAE market estimates, 2021 - 2033 (USD Million)

Fig. 33 Kuwait market estimates, 2021 - 2033 (USD Million)

Fig. 34 Strategy framework

## I would like to order

Product name: Middle East & Africa Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Type (Amyloid-related Markers, Tau-related Markers), By Technology, By End-use, By Country, And Segment Forecasts, 2025 - 2033

Product link: <https://marketpublishers.com/r/MDFA94DF7466EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MDFA94DF7466EN.html>